| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Profile: Anavex Life Sciences Corp
Posted on 11/02/2007 10:31:27 | Link | Post Comment
BHI Company Directory Profile
ANAVEX LIFE SCIENCES CORP
14 Rue Kleberg
CH-1201 Geneva
Switzerland
www.anavex.com
info@anavex.com
ANAVEX LIFE SCIENCES Corp. (AVXL.OB) is engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases, utilizing its proprietary drug discovery Sigmaceptor™ Technology Platform, consisting of a fairly new class of receptors, (sigma receptors), involved in the modulation of multiple cellular biochemical signaling pathways.
ANAVEX portfolio involves eleven new sigma ligands in late pre-clinical stage that target therapeutic areas of CNS and Cancer. These product candidates are expected to enter clinical trials within 2008.
ANAVEX’s Sigmaceptor-N program involves the discovery and development of novel and original drug candidates, targeting neurological and neurodegenerative diseases with urgent unmet medical needs such as, Alzheimer’s disease, Epilepsy, Depression, Multiple Sclerosis, Parkinson’s disease e.t.c. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence of anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anti-convulsive, anti-depressant and anxiolytic properties.
ANAVEX’s Sigmaceptor-C program involves the discovery and development of novel and original drug candidates targeting cancer. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as colon, prostate, breast and lung.
Preliminary results from in vivo studies in xenograft models have shown that ANAVEX lead compounds cause significant delay of tumor growth, suggesting a potent in vivo anticancer activity by inducing anoikis in a dose and time dependent manner.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
ANAVEX LIFE SCIENCES CORP14 Rue Kleberg
CH-1201 Geneva
Switzerland
www.anavex.com
info@anavex.com
ANAVEX LIFE SCIENCES Corp. (AVXL.OB) is engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases, utilizing its proprietary drug discovery Sigmaceptor™ Technology Platform, consisting of a fairly new class of receptors, (sigma receptors), involved in the modulation of multiple cellular biochemical signaling pathways.
ANAVEX portfolio involves eleven new sigma ligands in late pre-clinical stage that target therapeutic areas of CNS and Cancer. These product candidates are expected to enter clinical trials within 2008.
ANAVEX’s Sigmaceptor-N program involves the discovery and development of novel and original drug candidates, targeting neurological and neurodegenerative diseases with urgent unmet medical needs such as, Alzheimer’s disease, Epilepsy, Depression, Multiple Sclerosis, Parkinson’s disease e.t.c. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence of anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anti-convulsive, anti-depressant and anxiolytic properties.
ANAVEX’s Sigmaceptor-C program involves the discovery and development of novel and original drug candidates targeting cancer. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as colon, prostate, breast and lung.
Preliminary results from in vivo studies in xenograft models have shown that ANAVEX lead compounds cause significant delay of tumor growth, suggesting a potent in vivo anticancer activity by inducing anoikis in a dose and time dependent manner.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Millionaire Now! by Larry Nusbaum
- Ludwig von Mises Institute
- Credit Bloggers
- Don't Mess With Taxes
- Invest2Success
- Poor and Stupid
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Fri Jul 18, 2008 08:23AM
U.S. stock futures rebound on Citigroup results"S&a [read more]
U.S. stock futures rebound on Citigroup results"S&a [read more]
<< My Home | TheMoneyBlogs Home